FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150589138> ?p ?o ?g. }

• W2150589138 endingPage "664" @default.
• W2150589138 startingPage "660" @default.
• W2150589138 abstract "Sublingual‐specific immunotherapy (SLIT) is considered as a valid treatment of respiratory allergies. However, there are few data on large sample size regarding its clinical role in ‘real life’ in term of reduction of symptoms, rescue medications and prevention of asthma in patients suffering from allergic rhinitis (AR) especially in children. We performed a multicenter, case–control study to evaluate the effect of SLIT in children (age 6–18 yr) with intermittent or persistent AR. 171 children (27% girls and 73% boys) with AR due to seasonal or perennial allergens were enrolled in a multicenter case–control study. Cases (n = 90) were defined as patients with intermittent (64%) or persistent (36%) AR who were treated for at least two consecutive years with specific SLIT with the related allergen extracts (SLITone ® ALK‐Abellò). Controls (n = 81) were defined as sex‐age‐ and type of allergen matched AR children who were never treated with specific immunotherapy and had no asthmatic symptoms at the beginning of observation period. Main outcomes of the study were the rhinoconjunctivitis symptom score (SS) (sneezing, rhinorrea, nasal itch, congestion, ocular itch and watery eyes) with a ranging scale from 0 (=no symptoms) to 3 (=severe symptoms) and the medication score (MS) evaluating symptomatic drug intake (antihystamine and inhaled corticosteroids). SS and MS were evaluated at the end of the observational period in relation with the period, considering the last 12 months, in which patients suffered the highest symptoms levels (i.e., peak of relevant pollen season (seasonal AR) or during the period of maximum allergen exposure in case of perennial AR). Secondary outcome of the study was the development of asthma symptoms during the observation period. SS (mean ± SD) was 4.5 ± 2.5 in cases and 9.0 ± 3.0 in controls (−50%) (p = 0.0001). MS (mean ± SD) was 2.5 ± 1.9 and 3.6 ± 2.1 in the case and control groups, respectively (−31%) (p = 0.0001). At the end of the observation period asthma symptoms were present in 14 subjects in the case group (15%) and in 20 children (24%) in the control group (p = 0.13). New skin sensitizations appeared in 6% of cases (n = 2) and in 36% (n = 12) of the controls (p = 0.001). The EFESO trial shows that a 2‐yr once daily SLIT treatment in children with intermittent or persistent AR is associated with lower symptom and medication scores in comparison with subjects treated with symptomatic drugs only." @default.
• W2150589138 created "2016-06-24" @default.
• W2150589138 creator A5006028023 @default.
• W2150589138 creator A5035119103 @default.
• W2150589138 creator A5042449113 @default.
• W2150589138 creator A5046175437 @default.
• W2150589138 creator A5058235660 @default.
• W2150589138 creator A5058642614 @default.
• W2150589138 creator A5060719850 @default.
• W2150589138 creator A5065992365 @default.
• W2150589138 creator A5069490101 @default.
• W2150589138 date "2009-10-08" @default.
• W2150589138 modified "2023-10-16" @default.
• W2150589138 title "Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children Multicenter Trial" @default.
• W2150589138 cites W1984780114 @default.
• W2150589138 cites W1988331797 @default.
• W2150589138 cites W1996063904 @default.
• W2150589138 cites W2003860540 @default.
• W2150589138 cites W2015073683 @default.
• W2150589138 cites W2015712245 @default.
• W2150589138 cites W2037476918 @default.
• W2150589138 cites W2049494708 @default.
• W2150589138 cites W2060411425 @default.
• W2150589138 cites W2098913651 @default.
• W2150589138 cites W2108395554 @default.
• W2150589138 cites W2121760095 @default.
• W2150589138 cites W2132441138 @default.
• W2150589138 cites W2142010704 @default.
• W2150589138 cites W2147757792 @default.
• W2150589138 cites W2154126700 @default.
• W2150589138 cites W2155774990 @default.
• W2150589138 cites W2164132449 @default.
• W2150589138 cites W2165690383 @default.
• W2150589138 cites W2165933333 @default.
• W2150589138 cites W2171545556 @default.
• W2150589138 cites W2312829609 @default.
• W2150589138 cites W2319983832 @default.
• W2150589138 doi "https://doi.org/10.1111/j.1399-3038.2009.00860.x" @default.
• W2150589138 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19320852" @default.
• W2150589138 hasPublicationYear "2009" @default.
• W2150589138 type Work @default.
• W2150589138 sameAs 2150589138 @default.
• W2150589138 citedByCount "22" @default.
• W2150589138 countsByYear W21505891382012 @default.
• W2150589138 countsByYear W21505891382013 @default.
• W2150589138 countsByYear W21505891382014 @default.
• W2150589138 countsByYear W21505891382016 @default.
• W2150589138 countsByYear W21505891382017 @default.
• W2150589138 countsByYear W21505891382019 @default.
• W2150589138 countsByYear W21505891382021 @default.
• W2150589138 countsByYear W21505891382022 @default.
• W2150589138 countsByYear W21505891382023 @default.
• W2150589138 crossrefType "journal-article" @default.
• W2150589138 hasAuthorship W2150589138A5006028023 @default.
• W2150589138 hasAuthorship W2150589138A5035119103 @default.
• W2150589138 hasAuthorship W2150589138A5042449113 @default.
• W2150589138 hasAuthorship W2150589138A5046175437 @default.
• W2150589138 hasAuthorship W2150589138A5058235660 @default.
• W2150589138 hasAuthorship W2150589138A5058642614 @default.
• W2150589138 hasAuthorship W2150589138A5060719850 @default.
• W2150589138 hasAuthorship W2150589138A5065992365 @default.
• W2150589138 hasAuthorship W2150589138A5069490101 @default.
• W2150589138 hasConcept C126322002 @default.
• W2150589138 hasConcept C141071460 @default.
• W2150589138 hasConcept C168563851 @default.
• W2150589138 hasConcept C187212893 @default.
• W2150589138 hasConcept C199215989 @default.
• W2150589138 hasConcept C203014093 @default.
• W2150589138 hasConcept C207480886 @default.
• W2150589138 hasConcept C23131810 @default.
• W2150589138 hasConcept C2776042228 @default.
• W2150589138 hasConcept C2777844070 @default.
• W2150589138 hasConcept C2778311950 @default.
• W2150589138 hasConcept C2992435398 @default.
• W2150589138 hasConcept C54355233 @default.
• W2150589138 hasConcept C71924100 @default.
• W2150589138 hasConcept C86803240 @default.
• W2150589138 hasConceptScore W2150589138C126322002 @default.
• W2150589138 hasConceptScore W2150589138C141071460 @default.
• W2150589138 hasConceptScore W2150589138C168563851 @default.
• W2150589138 hasConceptScore W2150589138C187212893 @default.
• W2150589138 hasConceptScore W2150589138C199215989 @default.
• W2150589138 hasConceptScore W2150589138C203014093 @default.
• W2150589138 hasConceptScore W2150589138C207480886 @default.
• W2150589138 hasConceptScore W2150589138C23131810 @default.
• W2150589138 hasConceptScore W2150589138C2776042228 @default.
• W2150589138 hasConceptScore W2150589138C2777844070 @default.
• W2150589138 hasConceptScore W2150589138C2778311950 @default.
• W2150589138 hasConceptScore W2150589138C2992435398 @default.
• W2150589138 hasConceptScore W2150589138C54355233 @default.
• W2150589138 hasConceptScore W2150589138C71924100 @default.
• W2150589138 hasConceptScore W2150589138C86803240 @default.
• W2150589138 hasIssue "7" @default.
• W2150589138 hasLocation W21505891381 @default.
• W2150589138 hasLocation W21505891382 @default.
• W2150589138 hasOpenAccess W2150589138 @default.
• W2150589138 hasPrimaryLocation W21505891381 @default.
• W2150589138 hasRelatedWork W2016815862 @default.

• next